| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6183870 | Gynecologic Oncology | 2013 | 7 Pages |
ObjectiveEven in cases of early stage disease, uterine serous carcinoma (USC) is associated with high recurrence rates and a disproportionate number of cancer-related deaths. Prospective data to guide therapy for women with this disease are limited. This article reviews the currently available literature regarding optimal management of women with early stage USC.MethodsMEDLINE was searched for all research articles published in the English language from January 1, 1996 through October 30, 2012 in which the studied population included women diagnosed with early stage USC. Although preference was given to prospective studies, studies were not limited by design or numbers of patients in light of the relative paucity of the available literature.ResultsEarly stage USC (Stages I-II) is associated with a risk of recurrence that ranges from 0 to 80%, and is related to the amount of residual uterine disease, cervical involvement and adjuvant therapy. Treatment with platinum and taxane-based chemotherapy may decrease the risk of recurrence and may improve survival outcomes; volume directed radiotherapy may also be of benefit. USC highly expresses HER2/neu, a promising and rational target for biologic therapy. Alterations in the PIK3CA/AKT/ mTOR pathway are also of relevance and offer other potential therapeutic targets.ConclusionsUSC is a unique and biologically aggressive subtype of endometrial cancer, and as such, should be studied as a distinct entity. Prospective trials incorporating traditional chemotherapeutics and radiation as well as targeted therapies are warranted to define the optimal management approach for women with this disease.
⺠Patients with uterine serous carcinoma should be surgically staged. Adjuvant therapy with platinum/taxane-regimens improves survival. ⺠Uterine serous carcinoma highly expresses HER2/neu, a potentially promising and rational target for biologic therapy. ⺠Recent genome-wide analyses have contributed to the identification of key mutations that may further guide drug design against USC tumors.
